We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Review |

Drug Dosing and Pharmacokinetics in Children With Obesity A Systematic Review

Margreet W. Harskamp-van Ginkel, MD1,2,3; Kevin D. Hill, MD1,2; Kristian C. Becker, BA1,2; Daniela Testoni, MD, MHS1,2; Michael Cohen-Wolkowiez, MD, PhD1,2; Daniel Gonzalez, PharmD, PhD1,2,4; Jeffrey S. Barrett, PhD5; Daniel K. Benjamin Jr, MD, PhD, MPH1,2; David A. Siegel, MD6; Patricia Banks, BS1,2; Kevin M. Watt, MD1,2 ; for the Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee
[+] Author Affiliations
1Department of Pediatrics, Duke University, Durham, North Carolina
2Duke Clinical Research Institute, Duke University, Durham, North Carolina
3Academic Medical Center, Department of Public Health, Amsterdam, the Netherlands
4Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill
5Department of Clinical Pharmacology and Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
6Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland
JAMA Pediatr. 2015;169(7):678-685. doi:10.1001/jamapediatrics.2015.132.
Text Size: A A A
Published online

Importance  Obesity affects nearly one-sixth of US children and results in alterations to body composition and physiology that can affect drug disposition, possibly leading to therapeutic failure or toxic side effects. The depth of available literature regarding obesity’s effect on drug safety, pharmacokinetics, and dosing in obese children is unknown.

Objective  To perform a systematic literature review describing the current evidence of the effect of obesity on drug disposition in children.

Evidence Review  We searched the MEDLINE, Cochrane, and EMBASE databases (January 1, 1970-December 31, 2012) and included studies if they contained data on drug clearance, volume of distribution, or drug concentration in obese children (aged ≤18 years). We compared exposure and weight-normalized volume of distribution and clearance between obese and nonobese children. We explored the association between drug physicochemical properties and clearance and volume of distribution.

Findings  Twenty studies met the inclusion criteria and contained pharmacokinetic data for 21 drugs. The median number of obese children studied per drug was 10 (range, 1-112) and ages ranged from newborn to 29 years (1 study described pharmacokinetics in children and adults together). Dosing schema varied and were either a fixed dose (6 [29%]) or based on body weight (10 [48%]) and body surface area (4 [19%]). Clinically significant pharmacokinetic alterations were observed in obese children for 65% (11 of 17) of the studied drugs. Pharmacokinetic alterations resulted in substantial differences in exposure between obese and nonobese children for 38% (5 of 13) of the drugs. We found no association between drug lipophilicity or Biopharmaceutical Drug Disposition Classification System class and changes in volume of distribution or clearance due to obesity.

Conclusions and Relevance  Consensus is lacking on the most appropriate weight-based dosing strategy for obese children. Prospective pharmacokinetic trials in obese children are needed to ensure therapeutic efficacy and enhance drug safety.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1.
PRISMA Diagram of Study Selection

Study outline of the systematic literature search and inclusion of identified articles.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Relationship Between Obesity-Related Changes in Pharmacokinetics and Drug Physicochemical Properties

Volume of distribution and clearance ratios plotted by measured lipophilicity (logP) and Biopharmaceutical Drug Disposition Classification System (BDDCS) class. Clearance and volume of distribution are weight-normalized (eg, volume of distribution in L/kg). If authors did not report weight-normalized values (eg, for antipyrine, carbamazepine, and caffeine), then weight-normalized parameters were calculated by dividing reported values by individual or study mean weight values. A, Volume of distribution by measured logP; B, Volume of distribution by BDDCS class; C, Clearance by measured logP; D, Clearance by BDDCS class. ace indicates acetaminophen; ant, antipyrine; caf, caffeine; cbz, carbamazepine; dox, doxorubicin; eto, etoposide; gen, gentamicin; mer, mercaptopurine; mtx, methotrexate; ten, teniposide; the, theophylline; and van, vancomycin.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

5 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Promoción de la salud en el ciclo de vida